Celcuity Inc. has completed a $575 million convertible note offering, with net proceeds of $557.2 million earmarked for growth initiatives. This financing positions the company well for the upcoming commercial launch of its FDA-approved treatment, REVTORPYK, in late Q3 2026.

Key Highlights

  • Celcuity Inc. raised $575 million from a convertible note offering.
  • Net proceeds totaled $557.2 million, with $137 million used to prepay term Loan debt.
  • REVTORPYK is slated to launch in late Q3 2026, targeting advanced breast cancer treatments.

Celcuity Inc. (NASDAQ: CELC) has successfully completed a convertible note offering totaling $575 million, significantly enhancing its financial resources. The net proceeds from this transaction stand at $557.2 million and are critical for funding operational growth and supporting strategic initiatives. Of these funds, $137 million has already been allocated to prepay existing term loan debt, improving the company's financial flexibility as it gears up for upcoming product launches.

This fundraising marks a key step in strengthening Celcuity's balance sheet, enabling focused investments in high-potential projects.

Key Offering Details

The convertible note offering featured 0.250% senior notes due in 2032. The infusion of $557.2 million from the offering provides Celcuity Inc. with a strong Capital base as it prepares for operational advancements and the potential expansion of its clinical programs. This financial strategy allows the firm to align its resources adequately for critical project milestones and potential future growth opportunities.

By reducing Debt obligations with part of the proceeds, Celcuity reflects its commitment to maintaining a solid financial foundation while pursuing its strategic objectives.

Path to Commercialization

Celcuity is on track to initiate the commercial launch of REVTORPYK, its newly approved treatment for HR+/HER2- metastatic breast cancer, in late Q3 2026. Following FDA approval, which took place on July 14, 2026, the company has focused on establishing the necessary commercialization infrastructure. The recommendation of REVTORPYK in clinical guidelines reinforces its anticipated market entry.

This upcoming launch is built on Clinical Trials demonstrating the therapy's efficacy and safety in addressing significant unmet medical needs in breast cancer treatment.

Future Clinical Trials and Developments

In addition to the commercialization of REVTORPYK, Celcuity plans to submit a supplemental New Drug Application (sNDA) in the third quarter of 2026 based on promising results from a key clinical trial. The expansion of the VIKTORIA-2 trial will allow evaluation in previously untreated patients, putting Celcuity in a strong position to capture a broader patient segment. Submitting these data for regulatory review will be vital for scaling its product offerings and maximizing impact, signifying the company's focus on bringing innovative cancer treatments to market.

The next focus for Celcuity Inc. will be the upcoming insights from its clinical trials and the anticipated launch of REVTORPYK, as it aims to increase its footprint in the oncology sector with cutting-edge therapies.

Peers Moving on This News